Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Research Field Cancer, Drug delivery, Nanomedicine

Dendrimer DeLivery

The second largest cause of cancer-related deaths worldwide is liver cancer, which has been particularly hard to treat because it destroys the body’s ability to metabolize drugs, making responses to traditional small-molecule drugs unpredictable. A paper by Daniel Siegwart and colleagues suggests nanoparticles could be one potential solution (1).

“Advanced hepatocellular carcinoma (HCC) has a very poor prognosis with few therapeutic options. Sorafenib is the only available chemotherapeutic agent for HCC, and it extends median survival by only about 2.5 months,” says Siegwart. After seeing five small-molecule drugs fail Phase III clinical trials, partly due to drug toxicity, the team decided to explore alternative options for treatment.

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

About the Author

William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register